辛伐他汀联合运动训练对慢性阻塞性肺疾病稳定期合并代谢综合征患者临床观察

发布时间：2018-04-14 20:27

本文选题：辛伐他汀 + 慢性阻塞性肺疾病　；参考：《中国医院药学杂志》2015年09期

【摘要】：目的:观察辛伐他汀联合运动训练对慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)稳定期合并代谢综合征患者作用。方法:选取120例COPD稳定期合并代谢综合征(metabolism syndrome,MS)为研究对象,随机分为治疗A组、治疗B组及对照组各40例。治疗A组在常规治疗基础上加用辛伐他汀联合运动训练,治疗B组在常规治疗基础上加用辛伐他汀,对照组仅给予常规治疗,观察期为6个月。比较3组患者血清细胞因子白细胞介质(interleukin,IL)-6、IL-8与肿瘤坏死因子-α(tumor necrosis factor,TNF-α),胰岛素抵抗指数(homeostasis model assessment of insulin resistance,HOMA),脉搏波速度(pulse wave velocity,PWV),mMRC及6 min步行距离(6 minutes walking distance,6MWD),并对所获结果进行统计学分析。结果:6个月治疗后:(1)治疗A组及治疗B组的血炎症因子IL-6、IL-8与TNF-α较治疗前及对照组均明显下降,差异有统计学意义(P0.01);治疗组2组之间比较,A组较B组有明显下降,差异有统计学意义(P0.05);(2)治疗A组与治疗B组、对照组比较,HOMA有明显下降,差异有统计学意义(P0.05),但治疗B组与对照组比较,无明显差异(P0.05);(3)治疗A组、B组与对照组比较,PWV值有明显下降,差异有统计学意义(P0.05);治疗组2组之间比较,A组较B组PWV值下降,但无明显差异(P0.05);(4)治疗A组与治疗B组、对照组比较,mMRC及6MWD均明显改善,差异有统计学意义(P0.05);治疗B组较对照组比较,mMRC及6MWD均明显改善,差异有统计学意义(P0.05)。结论:辛伐他汀联合运动训练能降低COPD稳定期合并MS的IL-6、IL-8、TNF-α水平;改善胰岛素抵抗及大动脉弹性,并改善患者呼吸困难程度及运动能力。
[Abstract]:Aim: to observe the effect of simvastatin combined with exercise training on chronic obstructive pulmonary disease with metabolic syndrome.Methods: 120 COPD patients with metabolic syndrome were randomly divided into group A, group B and control group (n = 40).Group A was treated with simvastatin combined with exercise training on the basis of routine treatment, group B was treated with simvastatin on the basis of routine treatment, and control group was treated with routine therapy only, the observation period was 6 months.Serum cytokine IL-8 was compared with tumor necrosis factor- 伪 (TNF- 伪), insulin resistance index (ISR), model assessment of insulin resistance (HOMAA), pulse wave velocityn (PWV) MRC and 6 min walking distance (6 minutes walking distance 6MWD), and the results were statistically analyzed.Results: after 6 months of treatment, the levels of IL-6 IL-8 and TNF- 伪 in group A and group B were significantly lower than those in group A and group B, and the difference was statistically significant (P 0.01), while that in group A was significantly lower than that in group B, and that in group A was significantly lower than that in group B after 6 months of treatment, and the levels of IL-6 and TNF- 伪 in group A were significantly lower than those in group B.The difference was statistically significant (P 0.05) between group A and group B, and there was a significant decrease in HOMA in control group (P 0.05), but there was a significant difference between group B and control group, but there was no significant difference between group A and group B, but there was a significant difference between group B and control group.There was no significant difference in PWV between group A and group B (P 0.05), but there was no significant difference between group A (P 0.05) and group B (P 0.05), but there was no significant difference between group A (P 0.05) and group B (P 0.05), but there was no significant difference between group A and group B (P 0.05), and there was no significant difference between group A (P 0.05) and group B (P 0.05), but there was no significant difference between group A (P 0.05) and group B (P 0.05).Compared with the control group, the mMRC and 6MWD in the control group were significantly improved, the difference was statistically significant (P 0.05), while in the treatment group B, the mMRC and 6MWD were significantly improved compared with the control group (P 0.05).Conclusion: Simvastatin combined with exercise training can decrease the level of IL-6 and IL-8 TNF- 伪 in patients with COPD and MS, improve insulin resistance and arterial elasticity, improve the degree of dyspnea and exercise ability of patients.
【作者单位】：江汉大学附属医院呼吸内科;
【基金】：武汉市青年科技晨光计划项目(编号:201150431109)
【分类号】：R563.9;R589

【参考文献】